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Background:Metastasis of colorectal cancer to the liver is
the most common indication for hepatic resection in a
western population. Incomplete excision of malignancy
due to residual microscopic disease normally results in
worse patient outcome. Therefore, a method aiding in the
real time discrimination of normal andmalignant tissue on
a microscopic level would be of benefit.
Material and Methods: The ability of fluorescent probe-
based confocal laser endomicroscopy (pCLE) to identify
normal and malignant liver tissue was evaluated in an
orthotopic murine model of colorectal cancer liver metas-
tasis (CRLM). To maximise information yield, two clinical
fluorophores, fluorescein and indocyanine green (ICG)
were injected and imaged in a dual wavelength approach
(488 and 660nm, respectively). Visual tissue character-
istics on pCLE examination were compared with histologi-
cal features. Fluorescence intensity in both tissues was
statistically analysed to elucidate if this can be used to
differentiate between normal and malignant tissue.
Results: Fluorescein (488nm) enabled good visualisation of
normalandCRLMtissue,whereas ICG(660nm)visualisation
was limited to normal liver tissue only. Fluorescence intensity
in areas of CRLM was typically 53–100% lower than normal
hepatic parenchyma. Using general linear mixed modelling
and receiver operating characteristic analysis, high fluores-
cence intensity was found to be statistically more likely in
normal hepatic tissue.
Conclusion: Real time discrimination between normal
liver parenchyma and metastatic tissue with pCLE
examination of fluorescein and ICG is feasible. Employing
two (rather than a single) fluorophores allows a combina-
tion of qualitative and quantitative characteristics to be
used to distinguish between hepatic parenchyma and
CRLM. Lasers Surg. Med. 49:280–292, 2017.
 2016 The Authors. Lasers in Surgery and Medicine
Published by Wiley Periodicals, Inc.
Key words: liver metastases; confocal laser endomicro-
scopy; virtual histology; fluorescence microscopy; indo-
cyanine green; fluorescein
INTRODUCTION
Colorectal cancer is one of the most common cancers
globally, being the third most commonly diagnosed cancer
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Commons Attribution License, which permits use, distribution
and reproduction in any medium, provided the original work is
properly cited.
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endomicroscopy; ICG, indocyanine green; pCLE, probe-based
confocal laser endomicroscopy; CRLM, colorectal cancer liver
metastasis; ROC, receiver operating characteristics; RFU, rela-
tive fluorescence unit; GLIMMIX, generalised linear mixed
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inmen and secondmost common inwomen [1]. Up to a 50%
of patients develop liver metastases at some stage [2], a
condition which contributes to cancer related mortality in
about half of the affected patients [3]. Therapies directed at
liver metastases have, therefore, been subject of extensive
research interest [4].
Surgical resection of solid tumour metastases is the
preferred treatment for curative intent [5,6], resulting in
5-year survival rates approaching 60% [4]. Incomplete
tumour resection occur in up to 17% of cases and
detrimentally affect patient survival [7,8].Macroscopically,
colorectal cancer livermetastases (CRLM) usually exhibit a
white appearance that makes larger nodules easy to
distinguish from normal liver tissue, which appears brown.
Unfortunately, visual assessment is insufficient to
confirm complete tumour excision. Although intraoperative
ultrasonography (IOUS) and bi-manual palpation are
frequently used to determine tumour location within the
liver, this approach is not suitable to identify residual
cancer following resection because it is mainly of a
microscopic nature [9,10]. Identification of residual disease
using histopathology is not feasible during liver resection.
An imagingmodality that can confirmorrefute thepresence
of malignancy within liver tissue at a microscopic level
would, therefore, be helpful in ensuring complete resection,
reducing the amount of liver tissue resected, or to avoid an
unnecessary excision if cancer can be excluded [11].
Other imaging modalities such as cone beam CT,
magnetic resonance imaging and near infrared fluoroscopy
may be able to enhance imaging during liver surgery, but
none of these modalities provides an image resolution that
would enable identification of residual disease at a
microscopic level [12–14].
Optical imagingmodalities offermicrometer scale image
resolution but at this stage only optical coherence
tomography (OCT) and confocal laser endomicroscopy
(CLE) are available in compact designs that make an
intraoperative application feasible. Either imaging modal-
ity can visualise liver tissue ex vivo, but only CLE has been
extensively studied in an in vivo setting [15–18]. When
employed in a compact design, CLE has a better lateral
resolution than OCT at 1.4 versus 7mm [19,20]. This is an
important advantage of CLE which may allow imaging at
subcellular level in greater detail. CLE can be performed
with a bulkier rigid endomicroscope which contains the
required optics in its tip [21] or with a thin, flexible fibre-
based endomicroscope that conducts the excitation laser
and transmits signals to an external laser scanning
unit [17,22]. For the latter, a commercially available
solution is theCellvizioTM system (MaunaKeaTechnology,
Paris) which can be used in conjunction with fibre-optic
probes ranging from 0.3–4.5mm diameter.
Studies comparing confocal laser endomicroscopy (CLE)
with standard histology in animal models, have proven its
ability to visualise the cellular architecture of tissues,
thereby, providing a method of obtaining virtual, in vivo
histology in real-time [16,23]. In clinical practice, probe-
based confocal laser endomicroscopy (pCLE) is licensed for
the endoscopic diagnosis of gastrointestinal, bronchial and
urinary malignancy and dysplasia. Depending on the tissue
type, diagnostic accuracy is in the range of 86–91% [24–27].
Recent reportssuggest thatpCLEmayalsobeauseful tool for
the detection of breast and head and neck cancers [28,29].
To the best of our knowledge, the detection of liver
metastasis using pCLE has not been investigated previ-
ously. Therefore, this studywas conducted to assess towhat
extent dual wavelength pCLE imaging characteristics and
quantitative fluorescence properties could discriminate
betweenmetastatic and normal liver tissue in an orthotopic
nude mouse model of colorectal cancer liver metastases.
Dual wavelength CLE imaging was achieved by recording
measurementswith the CellvizioTM 488 and 660nmsystem
employing either fluorescein or indocyanine green as
fluorophores, respectively. Both fluorophores are clinically
licensed which enables findings to be translated into a
clinical context without safety concerns.
METHODS
Animal Model
All animal studies were approved by the University
College London Biological Services Ethical Review Com-
mittee and licensed under the UKHomeOffice regulations
and the Guidance for the Operation of Animals (Scientific
Procedures) Act 1986 (Home Office, London, United
Kingdom) and United Kingdom Co-ordinating Committee
on Cancer Research Guidelines for the Welfare and Use of
Animals in Cancer Research [30]. The human colorectal
carcinoma cell line SW1222 was cultured under aseptic
technique in Dulbecco’s Modified Eagles Medium contain-
ing 5mM L-glutamine and 10% v/v foetal bovine serum. All
animal studies were conducted in accordance with UK
home office regulations and the guidelines for the welfare
and use of animals in cancer research. The livermetastasis
model used has been previously described [31]. Briefly,
eight (n¼ 8) MF1 nu/nu mice (female, 6–8 weeks old,
25–30 g) underwent a laparotomy in order to directly inject
1 106 cells into the spleen. Splenectomy was performed
after 5 minutes to stop formation of a primary tumour at
the site of injection, with cells that had been carried by the
blood flow through to the liver forming the solid tumours of
the metastatic model. At conclusion of the procedure, the
laparotomy incision was closed and animals were recov-
ered. In the described animal model, female mice are
exclusively used due to their better compliance.
Liver tumour maturation took between 5 and 6 weeks.
The progression of metastatic disease was monitored once
per week with non-invasive magnetic resonance imaging
under general anaesthesia. The evolving disease pattern
showed a heterogeneous distribution of distinct solid
tumour nodules throughout the lobes of the liver, typically
comprising 10–20 tumour nodules that could be visualised
on magnetic resonance imaging.
CLE Image Acquisition
A transverse laparotomy was carried out under general
anaesthesia to allow unrestricted access to the liver. CLE
imaging at 488 and 660nm was performed with two
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different CLE imaging stacks with separate laser scanning
units, probes and image processing computers. Both
systems were initialised and calibrated at the start of
each experiment. Switching between wavelengths simply
required imaging probes to be swapped over. Due to the
inability of pCLE to visualise tissues beyond 100mmdepth,
images were exclusively acquired from superficial tissue,
while the probes were manually maintained in contact
with the liver surface. Motion artefact was reduced by
gently applying the pCLE probes onto the liver surface, so
that they moved in parallel with liver motion secondary to
respiration.
Images were acquired with the Z-probe at 488nm and
the mini-Z probe at 660nm wavelength. Probe character-
istics were the following: probe diameter 1.8 or 0.94mm;
lateral resolution 3.9mm, axial resolution 44 or 13mm,
working distance 80 or 65mm, maximal field of view
426302 or 323 323mm for the Z-probe or mini-Z probe,
respectively.
The liver was macroscopically categorised into normal
and cancerous tissue areas based on its respective brown or
white appearance. This approachwasmade possible by the
radically different appearance of normal liver versus
CRLM. Image sequences that were disturbed by excessive
motion artefact were not used, especially since they would
frequently included images from normal and cancerous
tissues at the same time. No attempt was made to identify
microscopic disease because the aim was to establish
reproducible CLE criteria of CRLM which could then be
translated to the detection of microscopic disease in future
studies. Baseline CLE images were recorded over a
representative area prior to fluorophore administration.
To provide exogenous fluorescence for CLE imaging at 488
and 660nm excitation, fluorescein sodium (molecular
weight 376.27 g/mol—henceforth called “fluorescein”) and
ICG (molecularweight 774.96 g/mol)weremixedwith 0.9%
sodium chloride or 5% dextrose, respectively. Subse-
quently, fluorescein (4–7mg/kg) and indocyanine green
(0.3–0.5mg/kg)were sequentially injected into the tail vein
with a delay of 20–40 minutes between injections to allow
adequate time for imaging. In preliminary experiments, it
was confirmed that neither fluorescein nor ICG elicited
unintentional “cross”-fluorescence signals.
An initial image sequence of 1–3minuteswas recorded to
monitor and confirm distribution of the fluorophores in the
liver. Several short sequences ranging from 10–20s were
taken from normal and malignant tissue in different
locations. The aim was to acquire images from as many
tumour nodules, and an equivalent number of normal liver
tissue areas, as possible. It was not feasible to co-register
tissue areas between 488 and 660nm pCLE imaging. But
due to the relatively small size of mouse livers, it was
hypothesised that approximately, the same areas of view
were imaged at both wavelengths. For statistical analysis
which is described below, all values for individual animals
were pooled into one group and hence co-registration is less
relevant than for the visual comparison of image features.
Pooling of data was also intended to decrease the impact
of heterogeneous fluorophore accumulation and tissue
scattering properties within the same animal. The mean
fluorescence values for each image frame from these
sequences were subsequently analysed.
Preparation and Examination of Tissue Samples
Following termination of the animals, the livers were
resected, fixed in 10% formalin and embedded in paraffin
blocks. Tissue sampleswere sliced at 4mmthicknesswith a
microtome and sections mounted on glass slides. The
presence of colorectal cancer metastases was confirmed by
using a standard structuralHaematoxylin andEosin stain.
Because areas of normal liver and CRLM in this disease
model looked radically different, histological examination
enabled us to confirm infiltration of adenocarcinoma cells
in representative liver areas which previously underwent
CLE in vivo examination.
Statistical Analysis
CellvizioTM is packaged with image analysis software
(ImagecellTM) that records and displays basic values
termed relative fluorescence units (RFU), from which the
maximum, minimum, median and mean were calculated
and exported for each image frame. Relative fluorescence
units are based on a reconstruction of single fibre
fluorescence intensity at a given point in time. A number
of factors such as fibre injection rate, fibre collection rate,
fibre auto-fluorescence, biological sample fluorescence and
laser source intensity influence fluorescence intensity.
These variables are factors in an equation that allows the
real time reconstruction of fluorescence intensity in
individual fibres each of which corresponds to an image
pixel of the CLE image. A detailed description of the
equation and other relevant methodology has been
previously published [32]. At the start of each imaging
session, a calibration is carried out using solution that
provides a uniform value of background fluorescence. The
calibration procedure results in homogenisation of the
individual probe fibres to give them uniform detection
sensitivity (which corresponds to a measured light
intensity) [33]. This process enables comparison of
fluorescence values between individual fibres (i.e. pixels)
of the probe, for a given calibration. However, whilst the
absolute background fluorescence value in the calibration
solution is uniform it may change between repeated
calibrations and different solution containers, meaning
that fluorescence units have to be regarded as relative, as
opposed to absolute values. Thus, imaging data were only
compared within the same animal.
NegativeRFUvalues either correspond to image noise or
can be caused by a reduction in fibre autofluorescence due
to prolonged illumination. To avoid misinterpretation,
negative RFU values were thresholded at zero. All RFU
values underwent a square root transformation to reduce
data skew and kurtosis as previously reported [20].
Routine statistical comparison, e.g. by paired Wilcoxon
rank sum test (individual animal pairedwithRFU)was not
possible due to specific constraints of the acquired data
whichwere: (1) unequal number of frame counts for normal
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and CRLM tissue and (2) potential introduction of a repeat
sampling error. These circumstances lead us to choose a
generalised linear mixed model (GLIMMIX) analysis
which can accommodate for the described data constraints
by estimating the interaction of fixed and random effects.
The GLIMMIX analysis enabled modelling of the proba-
bility of the acquired images corresponding to normal liver
parenchyma. The measured RFU value and animal ID
were set up as fixed effect and random effect for this model,
respectively. A similar approach has previously been used
by our group for CLE evaluation of ablated liver tissue in a
porcine model [20].
Different estimation methods such as Pseudo Likeli-
hood, Laplace and Gauss-Hermite quadrature can be used
for GLIMMIX analysis. For the purpose of this study, the
Laplace method was chosen because it exhibited satisfac-
tory convergence and the best fit characteristics as
assessed by Akaike information criterion (AIC). GLIMMIX
analysis results are given as the change in odds ratio for an
increase in RFU at a standardised value. For example, an
odds ratio of 2 at a standardised RFU increase of 100–101
means that the odds ratio of liver parenchyma being
normal increases by 2 if the RFU value increased by one
from 100 to 101.
To test the validity of the GLIMMIX model resulting
from the study data, a ROC analysis was performed.
The covariates and intercepts provided by the GLIM-
MIX analysis were used to calculate the log odds, odds
and finally, the probability of identifying normal liver
tissue. Each single probability value corresponded to a
single observation (mean RFU per frame), a specific
animal ID and a tissue type which enabled us to
perform a ROC analysis based on this data. Because
animal ID was a random effect due to the difference in
probe calibrations between experiments, the same RFU
value would result in different probability values for
individual animals.
To determine if a probability based threshold value could
be used to distinguish between normal and malignant
tissue random sample cross validation was carried out. To
this end, all observations were randomised into a training
and a validation dataset. The training set was used to build
a GLIMMIX prediction model whose output subsequently
underwent ROC analysis. A threshold value with an
optimal sensitivity and specificity for identifying normal
liver tissue was then chosen from the ROC curve
coordinates. This threshold probability value was subse-
quently applied to the validation set, to evaluate its
performance in distinguishing between normal and malig-
nant liver tissue and calculate the resulting sensitivity,
specificity and accuracy for this test.
An estimation of erythrocyte flow velocity calculated
from the available image data was also carried out. To
calculate flow velocity (in mm/s), the distance travelled by
a single erythrocytes in the time period between two image
frames (¼41.7ms at 24 frames per second) was measured.
Depending on the amount of available data, 5–10
individual erythrocytes were assessed per tissue type
and animal ID.
Statistically significant differences were assumed if
P<0.05. Statistical analysis was performed using SPSSTM
Version 21 (IBM, Armonk, NY) with exception of the
GLIMMIX analysis which was carried out with SASTM
Version 9.4 (SAS Institute, Cary, NC). Quantitative data
(RFU and erythrocyte flow velocity) is given asmedian and
interquartile range. Odds ratios are stated together with
their 95% confidence intervals (CI).
RESULTS
Test Sample Size
The orthotopic CRLM model was established in eight
mice. One animal died before any CLE measurements
could be carried out. The remaining sevenmice underwent
CLE examination. In two animals, the tumour burden
relative to normal liver was too great to allow meaningful
statistical comparison. Two animals died during image
acquisition; one (ID6) before sufficient data at either
wavelength could be collected and a further animal
following completion of CLE imaging with fluorescein at
488nm (ID7). In summary, six animals underwent
consequential CLE imaging and of these, four (fluores-
cein/488nm) and three (ICG/660nm) experiments pro-
vided sufficient data for statistical analysis.
Evaluating Normal Liver at 488nm Wavelength
With Fluorescein
Examples of CLE images and H&E histology for normal
and CRLM tissue are shown below. Each example is from
the same animal but due to the frequently small size of
lesions, no attempt was made to spatially correlate CLE
imageswith histological slides.Macroscopic lesion sizewas
larger than the pCLE field of view but otherwise variable
between animals. The smallest lesions were 1–2mm
whereas in some animals, the majority of the liver surface
was covered by metastatic deposits.
Prior to administration of fluorescein, no endogenous
fluorescence was observed in normal or metastatic tissue.
The initial period following fluorescein injection was
termed the inflowphase. During this phase, the fluorescein
strongly accumulated within the vascular compartment
and could be observed in hepatic sinusoids and interlobular
vessels (Fig. 1a). Occasionally, individual erythrocytes
could be visualised moving through blood vessels or
sinusoids. Because erythrocytes did not take up fluores-
cein, they could be seen as small, dark, round or discoid
shapes outlined against the bright contrast signal of the
intravascular fluorophore (Fig. 1b). Generally, inflow
phase images were dominated by a meshwork pattern of
bright interlobular vessels criss-crossing dark areas which
represented the parenchyma of liver lobules (Fig. 1c).
Inflow phase duration varied between animals but was
approximately 7–11 minutes. At the end of the inflow
phase, the fluorophore shifted from the intravascular
compartment to the liver parenchyma and connective
tissue, which resulted in high signal intensity within liver
lobules. This stage of the CLE examination, lasting
throughout the remainder of observations, was termed
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the parenchymal phase. Throughout its duration, cords of
hepatocytes and the sinusoid structure could frequently be
observed (Fig. 2a). Sinusoids and other liver vessels
appeared largely dark and devoid of fluorescence, and
this phenomenon became more marked at the later stages
of image acquisition.
Differentiation between types of vasculature (e.g. portal
vs. central venous vessels) was challenging at either
imaging phase but could sometimes be accomplished by
interpreting the vessel’s location and morphology. For
example, a central vein (which drains towards hepatic
vein) could be identified by its location and orientation
within the middle of a liver lobule (Fig. 2b).
Evaluating Liver Metastases at 488nm Wavelength
With Fluorescein
Areas of CRLM could be analysed in detail at 488nm
wavelength using fluorescein. The majority of malignant
Fig. 1. (a) A CLE image (488nm) showing fluorescein entering the intravascular space () shortly
after injection. (b) At completion of the inflow phase (>12 minutes after fluorophore injection),
hepatocyte cords appear dark (arrows), whereas the intravascular space which includes sinusoids
and larger lobular vessels is bright (). (c) Erythrocytes can be seen as dark shapeswithin the bright
intravascular space (arrows outline the blood vessel containing the erythrocytes). The remainder of
the image shows the typical pattern of normal liver parenchym consisting of amixture of hepatocyte
cords and sinusoids. (d) Histology of normal liver tissue with two blood vessels (arrows) containing
erythrocytes.
Fig. 2. (a) In the parenchymal phase of fluorescein administration, hepatocytes appear bright
(#marking examples) in CLE images (488nm) whereas the intravascular space () is dark due to
extravasation of thefluorophore into the interstitium. (b and c) The central vein () can be visualised
as a round area in themiddle of the hepatic lobulewith feeding sinusoid vessels (arrows) converging
towards it. (c) Histology with a similar configuration to the CLE image in b.
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tissue showed a pattern of dark patches criss-crossed by
bright linear structures. The areas devoid of fluorescence
represented malignant tissue which was interspersed by
torturous, neoangiogenic vessels that traversed through-
out the metastasis. Fluorescein appeared to be retained
within tumour vessels for longer than in the healthy
hepatic vasculature. This resulted in neoplastic vessels
displaying high intensity fluorescence throughout most of
the image acquisition. Infrequently, glandular structures
typical of moderate to well differentiated colonic malig-
nancy could be visualised (Fig. 3a).
Visible erythrocytes exhibited a mostly slow and erratic
movement when compared to normal hepatic vessels
(Fig. 3b and c). In two animals, there was sufficient image
data to estimate erythrocyte flow velocity in both tissue
types. Median flow velocity in normal tissue was
0.470.13 and 0.52 0.31mm/s compared to 0.180.15
and 0.15 0.1mm/s in CRLM tissue for animal ID1 and
ID8, respectively. Subjective discrimination between
normal and malignant tissue was feasible and a demarca-
tion line could be visualised in all animals (Fig. 3d and e).
Evaluating Normal Liver at 660nm Wavelength
With ICG
CLE examination at 660nm did not reveal any endoge-
nous fluorescence in areas of normal liver or CRLM tissue
prior to ICG injection. In contrast to CLE imaging at
488nm with fluorescein, no signal was detectable from
blood vessels during the inflow phase following ICG
administration, and erythrocyte movement could not be
visualised. In the parenchymal phase, however, structures
with the configuration of central lobular veins could be
identified (Fig. 4a). These had the typical appearance of
round, irregularly outlined structures, situated in the
centre of the lobule. During the parenchymal phase, ICG’s
high specificity for the cytoplasm of hepatocytes, resulted
in good visualisation of sinusoidal structures and allowed
distinction between hepatocytes and the surrounding
vasculature (Fig. 4b).
In general, blood vessels were identified as linear or
round structures that had a lower fluorescence signal,
relative to the surrounding hepatocytes. Because of the
prominent cytoplasmatic fluorescence, the nuclei of indi-
vidual hepatocytes were identifiable as dark intracellular
areas (Fig. 4c). Approximately, 15 minutes after injection
of ICG, bright regions of around 5–20mmdiameter could be
observed throughout the parenchyma. This phenomenon
possibly represents areas of ICG accumulation (e.g. bile
juice) (Fig. 4d).
Evaluating Liver Metastases at 660nm Wavelength
With ICG
In contrast to CLE imaging of fluorescein at 488nm,
areas of CRLM, as identified by visual inspection, did not
Fig. 3. (a) In the mouse model, fluorescein enhancement in CRLM tissue during the parenchymal
phase was characterised in CLE images by dark, irregular, round structures that retain some of the
original glandular architectural features that can also be seen on histology. The concentric
arrangement of adenocarcinoma cells (arrows) results in the “bullseye” appearance of a dark ring
around a bright centre on CLE and H&E histology. (b) Irregularly arranged vessels containing
erythrocytes () can be seen throughout the tumour tissue. In contrast to normal liver tissue, the
intravascular space within CRLM retained the circulating fluorophore throughout the entirety of
the observation period. (c) The corresponding histology features showing concentrically arranged
adenocarcinoma cells (arrows) and irregular vessels (). (d) The border (arrows) between normal
(bright) and cancerous tissue (dark) can be readily appreciated onCLE imaging. (e) Border between
normal and cancerous tissue on H&E histology.
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emit any measurable fluorescence and, therefore, ap-
peared as dark areas covering several fields of view
(Fig. 5a). Although no specific tumour characteristics
could be appreciated, it was possible to visualise the
delineation between CRLM and normal hepatic tissue by
observing a demarcation between high and low intensity
fluorescence areas (Fig. 5b).
Statistical Analysis of Fluorescence Values
RFU values measured during the parenchymal phase in
metastatic tissue were 53–94% lower for fluorescein/
488nm and 65–100% lower for ICG/660nm when com-
pared to normal liver tissue (Table 1, Fig. 6). GLIMMIX
analysis showed that higher RFU values measured during
the parenchymal phase were statistically significant
predictors for the presence of normal liver tissue at either
fluorophore and wavelength combination.
For the fluorescein/488nm combination, a RFU value
change from 37.8 to 38.8 increased the odds ratio of liver
tissue being normal (e.g. nonmetastatic) by 1.2 (P<0.0001,
CI 1.21–1.24). This was also true for the ICG/660nm
combination where a RFU value change from 10.5 to 11.5
Fig. 4. (a) A central vein (), acquired in vivo with CLE (660nm), surrounded by normal
parenchyma, acquired following ICG administration, which can also be seen in a corresponding
H&E image. (b) The distribution pattern of ICG mediated fluorescence enables discrimination
between sinusoids (thin arrows), larger blood vessels (wide arrow), and the hepatocytes, the latter of
which make up most of the image. Vessels and their bifurcations are represented by dark linear
structures (arrows). (c) Hepatocyte nuclei can be seen as small contrast sparing areas (thin arrows),
surrounded by bright cytoplasm. (d) At the end of the parenchymal phase, hepatocytes have lost
most of their fluorescence. Bright regions (arrows) spaced throughout the normal tissue likely
presents areas where bile juice is concentrated (e.g. bile ducts). (e) Section of normal liver histology
depicting a central vein (), nuclei (thin arrows), and larger interlobular vessels (wide arrows).
Fig. 5. (a) A CLE image of a region of CRLM, which is devoid of any fluorescence following ICG
administration. (b) An irregular transition (arrows) from low to high fluorescence represents the
demarcation line between CRLM and normal tissue in a CLE image acquired at 660nm. (c) The
border between metastasis and normal liver tissue viewed on H&E histology.
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resulted in an odds ratio increase of 4.6 (P< 0.0001, CI
3.8–5.7). The impact of treating individual animals as a
randomeffect did significantly contribute to the fit of either
model with a covariance parameter of 3.9 2.8 (SE,
P< 0.001) for fluorescein/488nm and 43.0 35.8 (SE,
P< 0.05) for ICG/660nm. The covariance parameter
estimation indicates to what degree the random variable
affects the fit of the mathematical model (e.g. aids in
predicting outcome) and its associated standard error gives
a measure of repeat sampling variability.
Subsequently, observations were randomised into a
training and validation set for each fluorophore and
wavelength combination. GLIMMIX analysis of the
training samples retained statistical significance with a
RFU increase from 37.7 to 38.7 and 10.6 to 11.6 resulting in
an odds ratio increase of 1.22 (P< 0.0001, CI 1.20–1.24)
and 5.08 (P< 0.0001, CI 3.62–7.12) for the fluorescein/
488nm and ICG/660nm combinations, respectively. Again
the random effect from performing measurements in
different animals did contribute to the fit of the model
with a covariance parameter of 3.8 2.7 (SE, P< 0.001) for
fluorescein/488nm and 49.2 42.0 (SE, P> 005) for
ICG/660nm.
ROC analysis of the training set resulted in an area
under the curve of 0.934 0.003 (CI 0.928–0.941) for
fluorescein/488nm and 0.994 0.001 (CI 0.992–0.997)
for ICG/660nm. A probability threshold value of 0.67 for
fluorescein/488nm and 0.69 for ICG/660nm (representing
a fixed RFU value and random animal effect) with a high
corresponding sensitivity and specificity was chosen from
the ROC curve coordinates. Based on these threshold
values, the validation set observations were categorised
into either normal ormetastatic tissuewhich consequently
enabled calculation of sensitivity and specificity for the
proposed quantification method. For the fluorescein/
488nm combination, sensitivity and specificity was
82.9% (CI 81.1–84.6%) and 85.2% (CI 83.2–87.0%) respec-
tively. For CLE imaging of ICG at 660nm wavelength, the
sensitivity and specificity was 97.9% (CI 97.0–98.6%) and
97.5% (CI 96.4–98.4%), respectively.
DISCUSSION
This article represents the first in vivo comparison of
dual-wavelength CLE imaging in combination with two
exogenous fluorescent probes as a method of differentiat-
ing liver metastases from normal liver parenchyma. The
CLE system used in this study allows high-resolution
(3.9mm), imaging of fluorescence with a field of view of
424302mm (488nm) or 323323mm (660nm), thereby,
allowing in vivo tissue structure and function evaluation in
real time.
Two distinct phases of CLE liver imaging, based on
fluorophore behaviour, have been described. The inflow
phase lasted up to 11 minutes and was characterised by
accumulation of fluorophore (and hence signal intensity) in
the intravascular space. Following on seamlessly, and
lasting for the remainder of the CLE examination, the
parenchymal phase showed a signal intensity shift to the
liver lobules. Images obtained in healthy liver tissue at
488nmwavelengthwith fluorescein provided good detail of
the sinusoidal structure and hepatic vascular architecture.
In contrast, CRLM tissue showed a pattern of tumour cell
agglomerations which were traversed by haphazardly
arranged blood vessels.
Quantitative estimation revealed that erythrocyte flow
velocity in CRLM tissue was slower than in normal liver
tissue. In contrast to healthy vessels that relatively quickly
lost fluorescence during the inflow phase, the signal
intensity in tumour vasculature remained high through-
out the inflow and parenchymal phases of imaging. This
was intriguing because, commonly, tumour vessels are
reported as having increased permeability [34] which can
lead to a rapid extravasation from the intra to the
extravascular compartment. This might have resulted in
rapid transfer of fluorescence from the vasculature to the
surrounding cancer tissue, whereas, in fact, the visualised
cancer tissue was largely devoid of signal which remains
unexplained by our experiments. This finding could
potentially be explained by a number of tumour specific
or general factors such as local tissue necrosis, systemic
hypoperfusion, arterio-venous shunts, or the unique
nature of the tumour cell line. Alternatively, tumour
vasculature associated factors such as reduced permeabil-
ity due to accelerated vessel maturation or volume
expansion of the extravascular space causing dilution of
fluorophore concentration could also be responsible for the
observed lack of fluorescence intensity. Without further
studies, it is difficult to put these findings into context
TABLE 1. Comparison of Relative Fluorescence Units in Normal Liver and Colorectal Cancer Liver Metastasis
488nm with fluorescein 660nm with ICG
Animal ID
Normal
(n¼ 2195)
CRLM
(n¼1922)
RFU change
(%)
Normal
(n¼ 2681)
CRLM
(n¼ 2050)
RFU change
(%)
1 3720 (2857) 226 (216) 94 126 (53) 0 (0) 100
2 2259 (760) 678 (308) 70 462 (150) 0 (0) 100
7 523 (164) 51 (128) 90   
8 2164 (1948) 1153 (1763) 53 310 (43) 110 (113) 65
Median RFU values in normal and CRLM tissue during the parenchymal phase are shown for each animal with the interquartile range
stated in brackets. Decrease of RFU from normal to CRLM tissue is shown in percent. Negative RFU values were thresholded to zero. ,
no data collection as animal expired during experiment.
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because to the best of our knowledge, pCLE imaging of a
comparable small animal model has not been reported in
the past.
Imaging at 660nmwavelength with ICGwas dominated
by the rapid uptake of ICG into the cytoplasm of normal
hepatocytes. Visualising the whole field of view enabled
sinusoid architecture to be identified, whereas on an
intracellular level, hepatocyte nuclei could be observed as
dark areas contrasted by the strong cytoplasmatic fluo-
rescence signal. Localised regions of high intensity
fluorescence that were seen at the later stage of imaging
could not reliably be attributed to a specific feature of liver
histology. Because ICG is known to be exclusively excreted
by bile [35], it is possible that these regions were small bile
ductules where the fluorophore accumulated before being
transported to the larger bile ducts. During image
acquisition, no vascular contrast could be observed but
occasionally vessels could be identified as dark linear or
circular structures outlined against the bright surround-
ing liver parenchyma.
Areas of CRLM were characterised by lack of ICG
mediated fluorescence purportedly due to the lack of ICG
uptake in the cancerous tissue. The absence of any relevant
imaging signal prevented the characterisation of CRLM
tissue with this wavelength and fluorophore combination.
The general finding was that fluorescein in combination
with CLE at 488nm was more suited to the imaging of the
vasculature and for examining CRLM morphology, which
was characterised by a mosaic of dark areas, irregular
vasculature and, occasionally, glandular structures. In
contrast, CLE imaging of ICG at 660nm appeared to be
better suited to assess the structure of sinusoids and the
surrounding hepatocytes.
Although some reports on in vivo CLE examination of
human liver disease have been published to date [17,36],
no data exists describing the application of CLE in liver
surgery for cancer. Several of the imaging features
described in this animal model, indicate that they could
be usefully translated to patients. For example, the
combination of glandular architecture and proliferation
of irregular vasculature with abnormal flow character-
istics, as observed on CLE examination of fluorescein at
488nm, is a common histological feature of human
CRLM [37–40]. A lack of ICG related fluorescence that
was apparent at 660nm has previously been reported
using camera based near-infrared imaging during liver
resection for colorectal metastases [14].
The feasibility of using CLE intraoperatively to confirm
complete removal of cancer in the resection of intracranial
malignancy has been demonstrated previously [41]. This
approach could also be of benefit during resection of CRLM,
where confirmation of malignancy at the borders of a
resection may allow a more radical procedure to be
performed with the intention of increasing cure rates. If
presence of microscopic malignancy can be excluded on the
other hand, it would allow surgeons to minimise
the resected total liver volume which in turn can reduce
the incidence of postoperative complications [42].
The same rationale can also be applied to ablation
therapy of CRLM which is emerging as a feasible
alternative or auxiliary treatmentmodality beside surgical
resection. In liver ablation, cancerous tissue is destroyed
by inducing coagulation necrosis through a variety of
methods (e.g. radiofrequency, microwave ablation) [43].
Our group has previously demonstrated in a porcinemodel
that laparoscopic pCLE enables discrimination between
normal and ablated liver tissue [20]. Due to the difficulties
of establishingmalignancy in a large animalmodel [44], no
pCLE examination of liver cancer was carried out. Because
Fig. 6. (a) Median RFU values95%CI comparison between
normal and CRLM tissue for each animal liver imaged at 488nm
with fluorescein. (b) Median RFU values95%CI comparison
between normal and CRLM tissue for each animal liver imaged at
660nm with ICG. Note that the median and 95%CI for CRLM
tissue in animal ID 1 and ID2 is zero and is, therefore, not
displaying on the bar chart.
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CellvizioTM and other non-commercial pCLE systems are
not yet licensed for clinical use during surgery, it was
crucial to investigate its potential benefit in an animal
model before considering its clinical evaluation.
In the current study, itwas demonstrated that utilising a
dual wavelength approach may be more advantageous
than using single wavelength CLE [17,36], because two
fluorophores and their respective imaging properties in
tissue can be evaluated in short succession. Fluorescein
and ICG CLE visualisation in hepatic tissue differs
because the former has properties suited to the visualisa-
tion of vasculature [36] whereas the latter is exclusively
cleared by the liver and, therefore, has a stronger affinity to
hepatocytes and bile ducts [35].
Other groups have explored the potential of CLE
imaging for identifying cancers and evaluated these in
animal models [16,45,46]. These, however, have been
based on nonclinically approved CLE systemswhichwould
need further development before they can be used in a
clinical context [23,45]. The experiments outlined here
were all performedwith aCEmarked device that has found
widespread interest for the clinical diagnosis of malig-
nancy [26,47–49] and it is hoped that the relatively
widespread dissemination of this CLE imaging platform
can help in facilitating the further clinical evaluation of the
findings presented here.
Previous articles on CLE imaging of malignancy have
been based on subjective, observer dependent image
interpretation but have not identified quantifiable and
reproducible parameters of malignancy [23,50]. To
establish such a quantifiable parameter that would allow
discrimination between normal and malignant liver, a
tissue evaluation centred on numerical fluorescence
values was proposed. A GLIMMIX analysis revealed
that normal liver tissue was more likely if high RFU
values were recorded with either wavelength and
fluorophore combination. Based on a random set of
observations, a threshold probability value for distin-
guishing normal liver from CRLM tissue has been
established for the measured CLE data. Subsequent
validation on the remaining observations revealed a very
good and excellent diagnostic accuracy of 83.9 and 97.8%
for the fluorescein/488 nm and ICG/660nm, combination,
respectively. Based on the diagnostic results in the
validation datasets, CLE imaging of ICG at 660nm may
be better suited for the use of fluorescence intensity to
discriminate between normal and CRLM tissue. The
superior performance when using CLE imaging of ICG at
660 nm for this purpose probably reflects the more
homogenous nature of CRLM tissue visualised with
this CLE setting. As described above, an abundance of
high intensity vascular structures seen with CLE
imaging of fluorescein at 488nm causes a heterogeneous
imaging pattern in areas of CRLM. Whether a combina-
tion of both fluorophore and wavelength combinations
can enhance diagnostic accuracy, could not be shown in
this study due to the inability of applying simultaneous
dual waveband CLE imaging to exactly the same field
of view. A new version of CellvizioTM capable of
simultaneous dual waveband imaging is now available
but we did not have access to this system for application
in this study.
Because probability values used for ROC analysis are
based on a combination of a fixed (RFU) and a random
effect (animal ID), it cannot be extrapolated into a specific
RFU value for future studies. Before this can be consid-
ered, it is crucial to standardise RFU value calibration
which could potentially result in reproducible and absolute
fluorescence units that could be globally applied across
different research groups.
Further limitations that have to be taken into account
regarding the presented findings pertain to the animal
model and the technical characteristics of confocal laser
microscopy. The animal model of CRLM that was studied
uses a human cancer cell line and a portal venous route of
establishing liver metastasis which is the most common
route of GI malignancy disseminating to the liver in
humans [51]. Despite these similarities, research on
murine models of malignancy have well-described limi-
tations when it comes to applying results to a clinical
setting [52]. A further issue is that experiments have
focused on a single cell line of colorectal neoplasia. This cell
line was chosen specifically because it exhibits a moderate
to well differentiated tumour histology that can display
colonic glandular architecture [53] and, therefore, was felt
to bemore visually distinct on CLE imaging. It is, however,
only representing a small spectrum of the histological
characteristics that CRLM may exhibit on virtual histol-
ogy and, therefore, further validation on different colorec-
tal cancer cell lines may be necessary. No formal liver
resection was carried out and, therefore, it is difficult to
predict if cutting into CRLM tissuewould lead to alteration
of its fluorescence properties.
A clear trend for lower fluorescence intensity in CRLM
compared to healthy liver tissue was especially prominent
on CLE imaging of ICG fluorescence, probably, because it
has a strong affinity for hepatic tissue. Colorectal cancer
liver metastasis is a common indication for surgical
resection of liver malignancy in the western hemisphere
and is generally regarded as the only curative treatment
option for this disease [54,55]. Some of our results may
become relevant for this patient population in the future,
but it is unlikely that these findings can be directly
transferred to primary liver malignancy (e.g. hepatocellu-
lar carcinoma), because fluorophore behaviour probably
depends on the organ of origin of the cancer. For example,
groups examining patients undergoing liver resection for
either CRLM or hepatocellular carcinoma, found de-
creased or increased ICG related fluorescence within
cancerous tissue, respectively [14,56].
Further restrictions that have to be accounted for are
related to the technology behind pCLE imaging. Optical
imaging modalities including CLE can visualise details
down to a sub-cellular level but at the cost of a limited
imaging depth. The maximal imaging depth of the
CellvizioTM probes used by our group was 0–70mm
depending on probe type, which means that only liver
cell architecture that is either superficial or adjacent to the
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resectionmargin could be assessed. It has been shown that
removal of tumour within an area of <1mm conveys a
patient survival benefit in the resection of CRLM [57].
Therefore, a potential use ofCLEwould be to confirm that a
resection margin is clear of cancer by probing the cut
surface. Because of CLE’s limited depth penetration, it
should not be considered as a potential substitute for
intraoperative ultrasound imaging but more as a comple-
mentary modality that expands the borders of intra-
operative imaging into the microscopic domain. The
CellvizioTM probes used in this study had a maximal field
of view of 600mm2 which may limit its applicability in the
clinical examination of liver resection margins which are
usually in the cm2-range. It has previously been shown,
however, that clinically relevant pCLE imagingwith afield
of view of approximately 2mm2 [17] is possible. Robotic
control of pCLE during laparoscopic liver surgery has been
utilised to create even larger fields of view [58]. If clinical
translation for intraoperative use of pCLE is considered, it
would be crucial to encourage the development of probes
that offer a field of view of 1mm2, because this would
greatly improve the integration of pCLE imaging into the
surgical workflow.
Currently, CellvizioTM probes are only marketed for
endoscopic applications and are not certified for intra-
operative use. Some of the probes, however, can be fully
sterilised and may potentially be used for imaging during
laparoscopic liver resection. If a clinical benefit for the
intraoperative usage of this system can be defined, sterility
issues and clinical re-certification should not present a
major obstacle.
In conclusion, a clinically licensed pCLE system was
used to provide a detailed description of discriminatory
tissue characteristics in an orthotopic murine model of
CRLM. A dual wavelength approach in conjunction with
two fluorophores was found to be of benefit because CLE
imaging of fluorescein at 488 nm enabled better visuali-
sation of metastatic tissue whereas quantification of ICG
mediated fluorescence intensity demonstrated a better
potential to objectively discriminate between normal
liver and CRLM tissue at a cellular level. Evaluation of
simultaneous (i.e. nonsequential) dual waveband imag-
ing and standardisation of fluorescence values is the
next crucial step to advance pCLE imaging of liver
malignancy.
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